McCullough Kristen (Kristen B McCullough, Kristen McCullough)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 39

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Newly Diagnosed

Top Venues

Blood cancer journal

American journal of hematology

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Marissa M Li, Anmol Baranwal, Mark Gurney, Syed Naseem Shah, Aref A Al-Kali, Hassan B Alkhateeb, James M Foran, Cecilia Arana-Yi, Laura Ongie, Dong Chen, Abhishek A Mangaonkar, McCullough Kristen, Ayalew Tefferi, Terra L Lasho, Christy M Finke, Mirinal S Patnaik, Mithun Vinod Shah
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood advances (2024)
Marissa M Li, Anmol Baranwal, Mark Gurney, Syed N Shah, Aref A Al-Kali, Hassan Alkhateeb, James Foran, Cecilia Arana-Yi, Laura Ongie, Dong Chen, Abhishek Mangaonkar, McCullough Kristen, Ayalew Tefferi, Terra Lasho, Christy Finke, Mirinal S Patnaik, Mithun Vinod Shah
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood advances 8 (12) (2024)
Marissa M Li, Anmol Baranwal, Mark Gurney, Syed N Shah, Aref A Al-Kali, Hassan Alkhateeb, James Foran, Cecilia Arana-Yi, Laura Ongie, Dong Chen, Abhishek Mangaonkar, McCullough Kristen, Ayalew Tefferi, Terra Lasho, Christy Finke, Mirinal S Patnaik, Mithun Vinod Shah
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood advances 8 (12) (2024)
Marissa M Li, Anmol Baranwal, Mark Gurney, Syed N Shah, Aref A Al-Kali, Hassan Alkhateeb, James Foran, Cecilia Arana-Yi, Laura Ongie, Dong Chen, Abhishek Mangaonkar, McCullough Kristen, Ayalew Tefferi, Terra Lasho, Christy Finke, Mirinal S Patnaik, Mithun Vinod Shah
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood advances 8 (12) (2024)
Ayalew Tefferi, Animesh D Pardanani, Aref A Al-Kali, Hassan Alkhateeb, McCullough Kristen, Mirinal S Patnaik, William J Hogan, Kebede H Begna, Michelle A Elliott, Nandita Khera, Jeanne M Palmer, Naseema Gangat, Katalin Kelemen, Attilio Orazi, Dong Chen, Kaaren K Reichard
Mast cell cytomorphology and treatment outcome in mast cell leukemia. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
McCullough Kristen
Do You See Me? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Rimal Ilyas, McCullough Kristen, Talha Badar, Mirinal S Patnaik, Hassan B Alkhateeb, Abhishek A Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood cancer journal 13 (1) (2023)
Naseema Gangat, Omer S Karrar, Moazah Iftikhar, McCullough Kristen, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. American journal of hematology (2023)
Nate Gipe, Nelson R Leung, Terra Lasho, Abhishek A Mangaonkar, Hassan Alkhateeb, Aref A Al-Kali, Naseema Gangat, William Hogan, McCullough Kristen, Ayalew Tefferi, Mariam Priya Alexander, Mirinal S Patnaik
Spectrum of renal pathological findings in patients with chronic myelomonocytic leukemia and kidney injury. American journal of hematology (2023)
Rimal Ilyas, McCullough Kristen, Talha Badar, Mirinal S Patnaik, Hassan B Alkhateeb, Abhishek A Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood cancer journal 13 (1) (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Rimal Ilyas, McCullough Kristen, Talha Badar, Mirinal S Patnaik, Hassan B Alkhateeb, Abhishek A Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood cancer journal 13 (1) (2023)
Rimal Ilyas, McCullough Kristen, Talha Badar, Mirinal S Patnaik, Hassan B Alkhateeb, Abhishek A Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood cancer journal 13 (1) (2023)
Mostafa Abdallah, McCullough Kristen, Rimal Ilyas, Kebede H Begna, Aref A Al-Kali, Mark R Litzow, William Joseph Hogan, Abhishek A Mangaonkar, Hassan B Alkhateeb, Mithun Vinod Shah, Michelle A Elliott, James M Foran, Talha Badar, Jeanne M Palmer, Cecilia Arana Yi, Lisa Sproat, Animesh Pardanani, Mirinal S Patnaik, Horatiu Olteanu, Rhett P Ketterling, Ayalew Tefferi, Naseema Gangat
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood cancer journal 13 (1) (2023)
Rimal Ilyas, McCullough Kristen, Talha Badar, Mirinal S Patnaik, Hassan B Alkhateeb, Abhishek A Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood cancer journal 13 (1) (2023)
Mostafa Abdallah, McCullough Kristen, Rimal Ilyas, Kebede H Begna, Aref A Al-Kali, Mark R Litzow, William Joseph Hogan, Abhishek A Mangaonkar, Hassan B Alkhateeb, Mithun Vinod Shah, Michelle A Elliott, James M Foran, Talha Badar, Jeanne M Palmer, Cecilia Arana Yi, Lisa Sproat, Animesh Pardanani, Mirinal S Patnaik, Horatiu Olteanu, Rhett P Ketterling, Ayalew Tefferi, Naseema Gangat
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood cancer journal 13 (1) (2023)
Mostafa Abdallah, McCullough Kristen, Rimal Ilyas, Kebede H Begna, Aref A Al-Kali, Mark R Litzow, William Joseph Hogan, Abhishek A Mangaonkar, Hassan B Alkhateeb, Mithun Vinod Shah, Michelle A Elliott, James M Foran, Talha Badar, Jeanne M Palmer, Cecilia Arana Yi, Lisa Sproat, Animesh Pardanani, Mirinal S Patnaik, Horatiu Olteanu, Rhett P Ketterling, Ayalew Tefferi, Naseema Gangat
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood cancer journal 13 (1) (2023)
Mostafa Abdallah, McCullough Kristen, Rimal Ilyas, Kebede H Begna, Aref A Al-Kali, Mark R Litzow, William Joseph Hogan, Abhishek A Mangaonkar, Hassan B Alkhateeb, Mithun Vinod Shah, Michelle A Elliott, James M Foran, Talha Badar, Jeanne M Palmer, Cecilia Arana Yi, Lisa Sproat, Animesh Pardanani, Mirinal S Patnaik, Horatiu Olteanu, Rhett P Ketterling, Ayalew Tefferi, Naseema Gangat
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood cancer journal 13 (1) (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology (2023)
Rimal Ilyas, McCullough Kristen, Talha Badar, Mirinal S Patnaik, Hassan B Alkhateeb, Abhishek A Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood cancer journal 13 (1) (2023)
Rimal Ilyas, McCullough Kristen, Talha Badar, Mirinal S Patnaik, Hassan B Alkhateeb, Abhishek A Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood cancer journal 13 (1) (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Abhishek A Mangaonkar, Kimberly J Langer, Terra L Lasho, Christy Finke, Mark R Litzow, William J Hogan, Mithun Vinod Shah, Ronald S Go, Gabriel Bartoo, Jade Kutzke, McCullough Kristen, Matthew Koster, Matthew Samec, Kenneth J Warrington, Kaaren K Reichard, Horatiu Olteanu, Mary Riwes, Mirinal S Patnaik, Hassan B Alkhateeb
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients. American journal of hematology (2022)
Ayalew Tefferi, Kebede H Begna, McCullough Kristen
Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day). American journal of hematology 97 (11) (2022)
Isla M Johnson, Evandro D Bezerra, Faiqa Farrukh, McCullough Kristen, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Mark R Litzow, William J Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Ayalew Tefferi, Naseema Gangat
Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood advances 6 (17) (2022)
Naseema Gangat, McCullough Kristen, Isla Johnson, Aref Al-Kali, Kebede H Begna, Mirinal S Patnaik, Mark R Litzow, William Hogan, Mithun Vinod Shah, Hassan Alkhateeb, Abhishek A Mangaonkar, James M Foran, Talha Badar, Jeanne M Palmer, Lisa Sproat, Cecilia Y Arana Yi, Animesh D Pardanani, Ayalew Tefferi
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. American journal of hematology 97 (6) (2022)
Naseema Gangat, Deandra Chetram, McCullough Kristen, Aref A Al-Kali, Kebede H Begna, William Hogan, Mark R Litzow, James Foran, Talha Badar, Jeanne Palmer, Mirinal S Patnaik, Animesh D Pardanani, Ayalew Tefferi
Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts. American journal of hematology 97 (12) (2022)
Maymona G Abdelmagid, Mark R Litzow, McCullough Kristen, Naseema Gangat, Animesh Pardanani, Hemant S Murthy, James M Foran, Rhett P Ketterling, David Viswanatha, Kebede H Begna, Ayalew Tefferi
Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases. Blood cancer journal 12 (7) (2022)
Mithun Vinod Shah, Abhishek A Mangaonkar, Kebede H Begna, Hassan B Alkhateeb, Patricia Greipp, Ahmad Nanaa, Michelle A Elliott, William Joseph Hogan, Mark R Litzow, McCullough Kristen, Ayalew Tefferi, Naseema Gangat, Mirinal S Patnaik, Aref A Al-Kali, Rong He, Dong Chen
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood cancer journal 12 (7) (2022)
Faiqa Farrukh, Deandra Chetram, Aref Al-Kali, James Foran, Mirinal S Patnaik, Talha Badar, Kebede H Begna, Christopher Hook, William Hogan, McCullough Kristen, Abhishek A Mangaonkar, Rong He, Naseema Gangat, Ayalew Tefferi
Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. American journal of hematology 97 (6) (2022)
McCullough Kristen, Alexis K Kuhn, Mrinal M Patnaik
Treatment advances for pediatric and adult onset neoplasms with monocytosis. Current hematologic malignancy reports 16 (3) (2021)
Joerg Herrmann, McCullough Kristen, Thomas M Habermann
How I treat cardiovascular complications in patients with lymphoid malignancies. Blood (2021)
Iuliana Vaxman, Jithma A Abeykoon, Angela Dispenzieri, Shaji K Kumar, Francis K Buadi, M Q Lacy, David Dingli, Y Hwa, A Fonder, M Hobbs, Craig B Reeder, T Sher, S Hayman, Taxiarchis V Kourelis, R Warsame, Eli Muchtar, N Leung, Ronald S Go, W Gonsalves, Mustaqeem A Siddiqui, R A Kyle, Sundararajan Vincent Rajkumar, McCullough Kristen, Prashant Kapoor, Morie A Gertz
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. Blood cancer journal 11 (12) (2021)
Maansi Joshi, Joselle Cook, McCullough Kristen, Ahmad Nanaa, Naseema Gangat, James M Foran, Hemant S Murthy, Mohamed A Kharfan-Dabaja, Lisa Sproat, Jeanne Palmer, Animesh Pardanani, Ayalew Tefferi, Kebede Begna, Michelle Elliot, Aref A Al-Kali, Mirinal S Patnaik, Mithun Vinod Shah, William Joseph Hogan, Mark R Litzow, Hassan B Alkhateeb
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood cancer journal 11 (3) (2021)
Allison P Golbach, McCullough Kristen, Scott A Soefje, Kristin C Cole, Tait D Shanafelt, Julianna A Merten
Evaluation of Burnout in a National Sample of Hematology-Oncology Pharmacists. JCO oncology practice (2021)
Thomas M Habermann, Arushi Khurana, Ruth Lentz, John J Schmitz, Alexander G von Bormann, Jason R Young, Christopher H Hunt, Sara N Christofferson, Grzegorz S Nowakowski, McCullough Kristen, Pedro Horna, Adam J Wood, William R Macon, Paul J Kurtin, Scott C Lester, Scott L Stafford, Ushrasree Chamarthy, Faraz Khan, Stephen M Ansell, Rebecca L King
Analysis and impact of a multidisciplinary lymphoma virtual tumor board. Leukemia & lymphoma 61 (14) (2020)
Erika Morsia, McCullough Kristen, Maansi Joshi, Joselle Madonna Cook, Hassan B Alkhateeb, Aref Al-Kali, Kebede H Begna, Michelle A Elliott, William Hogan, Mark R Litzow, Mithun Shah, Animesh Pardanani, Mirinal S Patnaik, Ayalew Tefferi, Naseema Gangat
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. American journal of hematology 95 (12) (2020)
Heather Personett May, Erin Frazee Barreto, McCullough Kristen, Ross Dierkhising, Nelson R Leung, Thomas M Habermann
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. Leukemia & lymphoma 60 (9) (2019)